These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

917 related items for PubMed ID: 23757301

  • 1. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH.
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME, Patnaik MM.
    Clin Epigenetics; 2016 Sep; 8():68. PubMed ID: 27307795
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L, Greil R.
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [Abstract] [Full Text] [Related]

  • 7. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE, Lübbert M.
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [Abstract] [Full Text] [Related]

  • 8. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [Abstract] [Full Text] [Related]

  • 9. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B, Robbel C, Wijermans P, Lübbert M.
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX, Xu L, Li X, Chang CK, Zhang Y, Wu LY, He Q, Zhang QX, Li X.
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [Abstract] [Full Text] [Related]

  • 11. Decitabine.
    Daskalakis M, Blagitko-Dorfs N, Hackanson B.
    Recent Results Cancer Res; 2010 Dec; 184():131-57. PubMed ID: 20072836
    [Abstract] [Full Text] [Related]

  • 12. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.
    J Clin Oncol; 2011 May 20; 29(15):1987-96. PubMed ID: 21483003
    [Abstract] [Full Text] [Related]

  • 13. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.
    Health Technol Assess; 2010 May 20; 14 Suppl 1():69-74. PubMed ID: 20507806
    [Abstract] [Full Text] [Related]

  • 14. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S, Li Z, Fu JH, Hu XH, Xu Y, Jin ZM, Tang XW, Han Y, Chen SN, Sun AN, Wu DP, Qiu HY.
    Asian Pac J Cancer Prev; 2015 May 20; 16(15):6627-32. PubMed ID: 26434886
    [Abstract] [Full Text] [Related]

  • 15. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS.
    J Natl Cancer Inst; 2009 Oct 07; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract] [Full Text] [Related]

  • 16. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
    Duong VH, Bhatnagar B, Zandberg DP, Vannorsdall EJ, Tidwell ML, Chen Q, Baer MR.
    Leuk Lymphoma; 2015 Jun 07; 56(6):1718-22. PubMed ID: 25263320
    [Abstract] [Full Text] [Related]

  • 17. The role of decitabine for the treatment of acute myeloid leukemia.
    Ganetsky A.
    Ann Pharmacother; 2012 Nov 07; 46(11):1511-7. PubMed ID: 23115225
    [Abstract] [Full Text] [Related]

  • 18. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y.
    Rinsho Ketsueki; 2014 Oct 07; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract] [Full Text] [Related]

  • 19. Clinical development of decitabine as a prototype for an epigenetic drug program.
    Rosenfeld CS.
    Semin Oncol; 2005 Oct 07; 32(5):465-72. PubMed ID: 16210087
    [Abstract] [Full Text] [Related]

  • 20. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
    Festuccia M, Baker K, Gooley TA, Sandmaier BM, Deeg HJ, Scott BL.
    Biol Blood Marrow Transplant; 2017 Sep 07; 23(9):1509-1514. PubMed ID: 28600031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.